trending Market Intelligence /marketintelligence/en/news-insights/trending/ilpKpRyFNWnAQkmuhTerVQ2 content esgSubNav
In This List

Sanofi pulls plug on Clostridium difficile vaccine

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sanofi pulls plug on Clostridium difficile vaccine

Sanofi decided to discontinue the development of its experimental Clostridium difficile vaccine.

Clostridium difficile is a bacterium that causes diarrhea and more serious intestinal conditions.

The company said its decision is based on an analysis by an independent data monitoring committee, which concluded that the probability of the vaccine meeting its primary objective in a phase 3 trial was low.

Sanofi was testing the vaccine in people at risk of the infection.

Sanofi Pasteur, the vaccines business of Sanofi responsible for the program, is informing all investigators, regulatory authorities and trial ethics committees.

Additionally, investigators are notifying study volunteers of the decision.